Danish pharmaceutical company Novo Nordisk, a major global insulin producer, confirmed a data breach exposing patient information from clinical trial programs. The incident involved unauthorized access to trial participant data stored in company systems. No details were provided about the scope, number of affected individuals, or breach timeline.

Why it matters in Western Canada: Western Canadian healthcare organizations and research institutions conducting clinical trials or collaborating with Novo Nordisk may need to assess whether their patient data or trial protocols were affected by this breach.

---

Summary generated from the original advisory. Read the full source: bleepingcomputer